Emerging pharmaceutical company in targeted therapies

MASITINIB IN THE TREATMENT OF AMYOTROPIC LATERAL SCLEROSIS (ALS)

20 MARCH 2017

This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable laws and regulation.

Neither the Company, nor any of its advisors and representatives may accept any responsibility for any loss or damage incurred by the use of this document or the information set forth herein. Neither the Company, nor any of its advisors and representatives takes any undertaking nor guarantees, whether explicitly or tacitly, the accuracy or the completeness of the information set forth herein.

In particular, in France, any decision to purchase such securities shall rely solely on the documents that have been reviewed by the Autorité des Marchés Financiers (the "AMF") and published by the Company.

This document does not constitute an offer to purchase any financial instruments in the United States. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. Any public offer of securities in the United States shall be made by means of a prospectus that may be obtained from the Company containing detailed information regarding the Company, its management and financial statements. The Company does not intend to register any offering in all or in part or to make a public offer of securities in the United States.

This document contains information on the objectives of the Company along with some projections. The reader's attention is drawn to the fact that these objectives may not be fulfilled, and the forecasts or information provided may prove erroneous, and the Company is not required to update such information. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser.

2

DESIGN OF ALS STUDY AB10015

RESULTS OF FINAL ANALYSIS

MECHANISM OF ACTION OF MASITINIB IN ALS INTELLECTUAL PROPERTY IN ALS

NEXT STEPS

UPDATE ON OTHER STUDIES

3

ALS - STUDY DESIGN

Study AB10015 is a pivotal, placebo controlled study with close to 400 patients.
  • Blinded, placebo controlled
  • 3 treatment-arms, randomisation 1:1:1

    • Masitinib 4.5mg/kg/day + riluzole

    • Masitinib 3mg/kg/day + riluzole,

    • Placebo + riluzole

  • Treatment duration : 48 weeks
  • Patients enrolled : 394 patients
  • Pre-planned interim analysis with 50% of patients enrolled treated for 48 week, which was positive

4

AB Science SA published this content on 22 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 March 2017 13:29:23 UTC.

Original documenthttp://www.ab-science.com/file_bdd/content/1490189020_SLAPresentationv03.2017vdef.pdf

Public permalinkhttp://www.publicnow.com/view/F51E6FCE9A8B75831C91D0DC96C1F8A331C3D185